Affinia Therapeutics Presents New Data and Updates on AAV Platform at American Society of Gene and Cell Therapy Annual Meeting
Share: WALTHAM, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Affinia Therapeutics, an innovative gene therapy company with a proprietary platform for rationally designed adeno-associated virus (AAV) vectors and gene therapies for rare and non-rare diseases, today announced results from preclinical studies presented in poster and oral sessions at the American Society of Gene and Cell Therapy (ASGCT) 24 Challenges in achieving adequate expression in the central nervous system (CNS) with conventional AAV vectors have limited the use of gene therapy to address many devastating rare and non-rare CNS ...
Source: benzinga.com